This trial is a multi-national, phase 2/3, open-label, randomized, controlled clinical study of utidelone injectable
Application being reviewed under the FDA Project Orbis framework, which enables concurrent reviews among US, Australia, Canada, Switzerland, Singapore and United Kingdom health authorities
PredOmix has developed a novel blood test that can detect about 32 cancers in both men and women with 98 percent accuracy
The committee voted that FDA should restrict use of LYNPARZA plus abi/pred to these BRCAm mCRPC patients
Clinic will offer Comprehensive Genetic Counselling and Testing Services to empower patients with personalized care
From cancer research to diagnostic solutions
ProBioGen previously developed the cell line and the manufacturing process and provided the initial clinical material for ImmunOs' innovative biologic.
It provides doctors with three indicators: identification of the bone, confirmation of device insertion into the bone, and notification in case of perforation through the opposite end of the bone
First approved therapeutic regimen that combines an anti-PD-1 and an antibody-drug conjugate in the US in these patients
Clinical data to date shows efti uniquely positioned to address entire NSCLC patient population through both chemo-free IO-IO and IO-IO-chemo triple combinations
Subscribe To Our Newsletter & Stay Updated
